drugset / Trial / NCT00075569
SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia
Phase 2
Completed
64 enrolled
Albert Einstein College of Medicine
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer or to treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia. PURPOSE: This phase II trial is studying how well SGN-00101 immunotherapy works in preventing cervical cancer in patients with grade III cervical intraepithelial neoplasia.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-08
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VERPASEP CALTESPEN | Vaccine | 500 ug | Subcutaneous |